According to latest study, the U.S. cancer biopsy market size was valued at USD 10.21 billion in 2023 and is projected to surpass around USD 29.34 billion by 2033, registering a CAGR of 11.13% over the forecast period of 2024 to 2033.
According to latest study, the U.S. cancer biopsy market size was valued at USD 10.21 billion in 2023 and is projected to surpass around USD 29.34 billion by 2033, registering a CAGR of 11.13% over the forecast period of 2024 to 2033.
Drivers for the U.S. cancer biopsy market include technological advancements, rising cancer incidence rates, demand for personalized medicine, and increased healthcare spending.
Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/6586
U.S. Cancer Biopsy Market overview
The U.S. cancer biopsy market refers to the sector within the healthcare industry focused on the procurement, analysis, and diagnosis of cancerous tissues or cells extracted from a patient’s body. Biopsy procedures are crucial for confirming the presence of cancer, determining its type, and guiding treatment decisions.
In this market, various techniques such as needle biopsies, surgical biopsies, and liquid biopsies are employed to obtain tissue samples for examination by pathologists and oncologists. These samples are then analyzed using advanced imaging technologies, molecular diagnostics, and histological evaluations to identify specific biomarkers indicative of cancer.
The application of cancer biopsies extends across numerous medical disciplines, including oncology, pathology, radiology, and molecular biology. Biopsy results play a vital role in staging cancer, assessing its aggressiveness, monitoring treatment response, and predicting patient prognosis. Moreover, advancements in biopsy techniques and technologies, such as precision medicine and liquid biopsies, are driving innovation in cancer diagnosis and personalized treatment strategies, thereby shaping the evolution of the U.S. cancer biopsy market.
Regional instances
- The U.S. dominates the cancer biopsy market due to several factors. Firstly, it has a robust healthcare infrastructure with advanced medical technology and research facilities. Secondly, there’s a high prevalence of cancer cases, driving demand for biopsy procedures. Additionally, the presence of leading biotech and pharmaceutical companies fosters innovation and product development. Moreover, favorable reimbursement policies and a large patient pool contribute to market growth. Regional instances include top-notch medical centers like Mayo Clinic and MD Anderson, as well as collaborations between academia and industry, further solidifying the U.S.’s position in the cancer biopsy market.
- In 2022, breast cancer claimed the lives of 670,000 individuals worldwide, highlighting its significant global impact. Surprisingly, roughly half of all breast cancer cases occur in women without specific risk factors other than their sex and age, underlining the pervasive nature of the disease. Moreover, breast cancer emerged as the most prevalent cancer among women in 157 out of 185 countries surveyed, illustrating its widespread occurrence. Notably, breast cancer knows no geographical boundaries, affecting populations in every country across the globe. Additionally, while breast cancer is predominantly associated with women, approximately 0.5–1% of cases also affect men, emphasizing the importance of awareness and early detection efforts across all demographics.
Cancer Biopsy Market Size in the Global 2024 to 2033
The global cancer biopsy market size was estimated at USD 25.35 billion in 2023 and is projected to hit around USD 134.96 billion by 2033, growing at a CAGR of 18.2% during the forecast period from 2024 to 2033. North America led the market with the largest market share of 41.85% in 2023.
Immediate Delivery Available, Get Full Access@
https://www.novaoneadvisor.com/report/checkout/6586
U.S. Cancer Biopsy Market Dynamics
Driver
Advancements in precision medicine
The U.S. cancer biopsy market is experiencing significant growth driven by advancements in precision medicine. Tailored treatments based on individual genetic profiles and tumor characteristics are becoming increasingly common, necessitating accurate and comprehensive biopsy procedures for diagnosis and molecular analysis. As precision medicine gains traction, there’s a heightened demand for biopsy techniques capable of providing detailed information about the specific molecular markers and mutations driving cancer progression. This emphasis on personalized treatment strategies fuels the adoption of innovative biopsy technologies and drives market expansion as healthcare providers strive to offer patients the most effective therapies tailored to their unique cancer profiles.
- In November 2023, Grail initiated the Medicare Multi-Cancer Early Detection Study, evaluating the clinical efficacy of its Galleri multi-cancer early detection test among Medicare beneficiaries. With a targeted focus on racial and ethnic minorities in underserved communities, this study aims to assess the test’s impact on improving cancer detection and healthcare equity.
Restraint
Patient anxiety and compliance
Patient anxiety and reluctance to undergo biopsy procedures due to fear of pain, complications, or the invasiveness of the process can impede diagnosis and treatment, impacting market growth and patient outcomes. This anxiety can lead to delayed or avoided biopsies, resulting in missed opportunities for early detection and intervention. Additionally, non-compliance with biopsy recommendations can hinder the accuracy of diagnosis and the effectiveness of treatment plans, exacerbating the challenges of managing cancer. Addressing patient concerns through education, improved communication, and the development of less invasive biopsy techniques is essential to mitigate these restraints and enhance overall market performance.
Opportunity
Integration of AI in transforming the U.S. cancer biopsy market
Integration of artificial intelligence (AI) presents promising opportunities for the U.S. cancer biopsy market. AI can revolutionize biopsy analysis by augmenting accuracy, speed, and efficiency. Through advanced algorithms and machine learning, AI can enhance diagnostic precision, leading to earlier detection and more personalized treatment approaches. Moreover, AI-driven biopsy analysis can streamline workflows, reducing time-to-diagnosis and enabling prompt interventions. By leveraging AI, healthcare providers can unlock new insights from biopsy data, facilitating more informed treatment decisions and ultimately improving patient outcomes. The integration of AI thus represents a transformative opportunity to advance cancer care in the United States.
- In March 2024, GE HealthCare debuted Prostate Volume Assist, an AI-powered software designed for ultrasound, streamlining prostate volume measurements with automated one-click functionality. This innovation aims to expedite workflows in prostate imaging and ultrasound-guided procedures, offering clinicians efficient and accurate tools for diagnosis and treatment planning.
U.S. Cancer Biopsy Market Recent advancements
- In February 2024, Continental Hospitals Introduced Early Detection Liquid Biopsy Test, a groundbreaking cancer detection mechanism. This blood test promises earlier cancer detection, potentially saving lives. Doctors hail it as a less invasive and more accessible approach to early detection, marking a significant advancement in cancer diagnosis and treatment.
- In October 2023, Delfi Diagnostics introduced FirstLook Lung, its inaugural liquid biopsy test, fulfilling its vision of offering a blood-based screening tool for lung cancer. With a sensitivity delivering a 99.7% negative predictive value, this test aims to revolutionize lung cancer detection, offering a convenient and accessible option for at-risk populations.
By Site (Organ) Insights
Breast cancer segment accounted for the largest revenue share of 22% in the U.S. cancer biopsy market in 2023. The dominance of the segment is attributed to the increasing prevalence of breast cancer aided by the growing recommendation for suspected cancer patients to undergo microscope-based analysis of breast tissue, which helps doctors conclude on a definitive diagnosis along with detecting stage and characterization of the disease.
This has propelled the demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis. Image-guided needle biopsy has emerged as a safe and accurate nonsurgical approach for diagnosing suspicious tissues in the breast. These diagnostic approaches yield findings that are integral for designing apt therapeutic methods.
Thyroid segment is expected to show the fastest growth during the forecast period. Thyroid cancer is a comparatively infrequent malignancy that accounts for about 2.0% of cancer cases in men and less than 1.0% to 5.0% in women. Fine-needle aspiration (FNA) biopsy is the most accurate test for detecting malignancy in thyroid patients; it can be pivotal in the effective evaluation of thyroid nodules.
Several studies suggested that results obtained through FNA are superior when combined with Ultrasound Guidance (USFNA). Techniques such as palpation-directed FNA and Ultrasound-directed (US) FNA are set to gain traction in this segment. High demand for FNA is also a result of routine usage of US FNA across follow-up surveillance of thyroid cancer patients.
By product
In the U.S. cancer biopsy market, the kit and consumables segment reigns supreme, commanding a dominant position. This segment encompasses a wide array of essential products necessary for biopsy procedures, including needles, reagents, and specimen containers. Its dominance underscores the critical role these consumables play in the biopsy process, facilitating accurate diagnosis and treatment decisions. With ongoing advancements in technology and increasing demand for precision medicine, the kit and consumables segment is poised for continued growth, driving innovation and improvements in cancer care across the United States.
By type
The U.S. cancer biopsy market is primarily dominated by tissue biopsies, including fine needle aspiration (FNA), core needle biopsy (CNB), needle biopsies, and surgical biopsies. These methods are crucial for obtaining tissue samples for diagnostic purposes, guiding treatment decisions, and monitoring disease progression. Tissue biopsies offer high accuracy in identifying cancerous cells and provide valuable information for personalized treatment strategies. As a result, they remain the cornerstone of cancer diagnosis and management in the United States, contributing significantly to the overall market share in cancer biopsy procedures.
By Application
In the U.S. Cancer biopsy market, the breast cancer segment stands out as the dominant force. This may be due to several factors such as the prevalence of breast cancer, extensive screening programs, and advancements in biopsy technologies tailored for breast tissue analysis. With a focus on early detection and personalized treatment, the emphasis on breast cancer biopsy underscores the importance of accurate diagnosis and targeted therapies in improving patient outcomes. As a result, investments in research, development, and healthcare infrastructure often prioritize innovations within this segment to address the growing burden of breast cancer in the United States.
Related report:
Liquid Biopsy Market : https://www.biospace.com/article/releases/liquid-biopsy-industry-is-rising-rapidly-up-to-usd-32-54-bn-by-2033/
Synthetic Biology Market : https://www.biospace.com/article/synthetic-biology-industry-is-rising-rapidly-up-to-usd-80-17-bn-by-2033/
Pharmaceutical CDMO Market: https://www.biospace.com/article/releases/pharmaceutical-cdmo-industry-is-rising-rapidly-up-to-usd-295-95-bn-by-2033/
Biomarkers Market : https://www.biospace.com/article/releases/biomarkers-market-size-to-hit-usd-284-76-billion-by-2033/
Biotechnology Market: https://www.biospace.com/article/biotechnology-market-size-to-reach-usd-5-68-trillion-by-2033/
Clinical Trials Market : https://www.biospace.com/article/releases/clinical-trials-market-size-to-increase-usd-153-59-billion-by-2033/
U.S. Clinical Trials Market: https://www.biospace.com/article/releases/u-s-clinical-trials-market-size-industry-analysis-report-2033/
U.S. Biotechnology Market: https://www.biospace.com/article/releases/u-s-biotechnology-market-size-to-increase-usd-1-79-trillion-by-2033/
Oncology Clinical Trials Market: https://www.biospace.com/article/releases/oncology-clinical-trials-market-experiencing-rapid-growth/
Diagnostic Testing Market : https://www.biospace.com/article/releases/diagnostic-testing-market-size-to-reach-usd-449-78-billion-by-2033/
Genomics Market: https://www.biospace.com/article/releases/genomics-market-size-to-hit-usd-157-47-billion-by-2033/
Biologics Market: https://www.biospace.com/article/biologics-market-size-to-hit-around-usd-1-37-trillion-by-2033/
Biochip Market https://www.biospace.com/article/biochip-market-size-to-hit-around-usd-40-49-billion-by-2033/
Single-use Bioprocessing Market : https://www.biospace.com/article/releases/single-use-bioprocessing-market-size-to-increase-usd-128-24-bn-by-2033/
Breast Cancer Diagnostics Market: https://www.biospace.com/article/breast-cancer-diagnostics-market-size-share-and-growth-report-2033/
U.S. Cancer Biopsy Market Top Key Companies:
- BD (Becton, Dickinson And Company)
- IZI Medical Products
- Johnson & Johnson Services, Inc.
- Argon Medical
- Spectra Medical Devices, Inc.
- Medtronic
- Boston Scientific Corporation
- CONMED Corporation
- INRAD, Inc.
- Thermo Fisher Scientific, Inc.
U.S. Cancer Biopsy Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Cancer Biopsy market.
By Product
- Instruments
- Kits And Consumables
- Services
By Type
- Fine-needle Aspiration
- Pharma-use
- Clinical
- Core Biopsy
- Pharma-use
- Clinical
- Surgical Biopsy
- Pharma-use
- Clinical
- Skin Biopsy /Punch Biopsy
- Pharma-use
- Clinical
- Others
- Pharma-use
- Clinical
By Application
- Screening & Monitoring
- Diagnostics
- Investigational & Translational Research
- Pharma & Biopharma Discovery & Development
By Site (Organ)
- Liver
- Breast
- Thyroid
- Prostate Gland
- Uterus & Cervix
- Kidney
- Bladder
- Lungs
- Pancreas
- Others
Immediate Delivery Available | Buy This Premium Research
https://www.novaoneadvisor.com/report/checkout/6586
Frequently Asked Questions
- What geographic regions does your market research cover for the U.S. Cancer Biopsy market?
- We have a global reach, with expertise spanning across continents, including North America, Europe, Asia-Pacific, Latin America, and the Middle East. We leverage a combination of primary and secondary research methodologies to offer country-level analysis.
- How does your firm conduct cross-sectional analysis for the U.S. Cancer Biopsy market?
- We conduct cross-sectional analysis by examining data from different individuals at a single point in time to identify patterns and trends across diverse segments of the market.
- Can your firm customize market research solutions to meet specific client needs?
- Our experienced team works closely with clients to gain a thorough understanding of their business goals and target markets. We have the expertise and flexibility to develop bespoke research solutions.
- Do you offer ongoing support or consultation to clients after the completion of a market research project?
- Our team of experienced analysts is available to address any questions, concerns and needs that may arise following the delivery of the report.
- Can your market research firm help with competitor analysis for U.S. Cancer Biopsy market?
- Through a combination of quantitative and qualitative research methodologies, we meticulously assess the strengths, weaknesses, strategies, and market positioning of your competitors.
Order the 150+ Pages Detailed Report @ https://www.novaoneadvisor.com/report/checkout/6586
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: sales@novaoneadvisor.com
